top of page
This site was designed with the
.com
website builder. Create your website today.Start Now

Clinical Trials

  1. Aspen – Veteran Affairs Hospital (December 2013 – June 2015)

    • Chronic Opioid Use in Lower Back Pain and Lumber Orthosis Intervention

  2. ​Cebix – CBX129801-DN-201 (December 2012 – June 2013)

    • A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (ErsattaTM), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects with Mild to Moderate Diabetic Peripheral Neuropathy

  3. GlaxoSmithKline – GLP114856 (June 2012 – February 2013)

    • A Multidose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Pharmacokinetics and Pharmacodynamics of Albiglutide

  4. Sanofi Aventis – ACT11917 (March 2012 – June 2013)

    • Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

  5. Intarcia Therapeutics – ITCA 650-CLP-103 (March 2013 – June 2013)

    • Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes

  6. Eli Lilly and Company – I2R-MC-BIAK (February 2013 – June 2013)

    • A Comparison of LY2605541 Versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With 2 or More Oral Antihyperglycemic Medications: An Open-Label, Randomized Study

  7. Eli Lilly and Company – I2R-MC-BIAX (February 2013 – June 2013)

    • A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study

  8. Merck – MK-3102-024 (January 2013 – June 2013)

    • A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy

  9. Eli Lilly and Company – I2R-MC-BIAM (August 2012 – June 2013)

    • The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin With Insulin Lispro: a Double-Blind, Randomized, 26-week Study - The IMAGINE 4 Study

  10. Eli Lilly and Company – I2R-MC-BIAO (August 2012 – June 2013)

    • The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: a Double-Blind, Randomized, 52-week Study

  11. Gilead Sciences – GS-US-259-0147 (July 2012 – February 2013)

    • A Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled On Metformin Alone

  12. Eli Lilly and Company – I2R-MC-BIAJ(a) (May 2012 – June 2013)

    • A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naive Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study

  13. GlaxoSmithKline – GLP112754 (May 2012 – March 2013)

    • A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus

  14. Astellas – E05-CL-3004 (April 2012 – June 2013)

    • A Double-blind, Randomized, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of QUTENZA® in Subjects With Painful Diabetic Peripheral Neuropathy

  15. Merck – MK-0431E-211 (March 2012 – February 2013)

    • A Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

  16. Bristol-Myers Squibb – MB102-073 (February 2012 – April 2013)

    • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

  17. Bristol-Myers Squibb – MB102-077 (February 2012 – April 2013)

    • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication

  18. Sanofi Aventis – EFC11628 (February 2012 – June 2013)

    • 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both Plus Mealtime Insulin in Patients With Type 2 Diabetes Mellitus With a 6-month Safety Extension Period

  19. Sanofi Aventis – EFC11629 (February 2012 – June 2013)

    • 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period

bottom of page